Full-Time
Senior Infrastructure Engineer
SRE & Devops
Confirmed live in the last 24 hours
Genesis Therapeutics
51-200 employees
AI-driven drug discovery for pharmaceuticals
No salary listed
Senior
Burlingame, CA, USA
This is a hybrid position, which implies that the candidate will be required to work in-office for part of the week.
- 5+ years of experience building and maintaining cloud infrastructure at scale, e.g. within AWS or GCP
- Proficient with Python, Bash, Terraform, and Kubernetes
- Ideally, experience building and maintaining compute clusters running distributed ML training jobs with 1,000+ GPUs
- Nice to have: hands-on experience with physical hardware + datacenter management
- Work on our infrastructure team to maintain and grow our multi-cloud compute infrastructure that supports our ML model training, computational chemistry research, and ongoing drug discovery efforts
- Build out our configuration and procedures for monitoring, resource allocation, and deployment automation, as we continue to grow our autoscaling compute clusters to handle larger workloads
- Work on orchestration scheduling framework to increase our execution throughput, reliability, and compute utilization across heterogeneous pipelines
- Ideally, experience building and maintaining compute clusters running distributed ML training jobs with 1,000+ GPUs
- Nice to have: hands-on experience with physical hardware + datacenter management
Genesis Therapeutics focuses on developing new medicines by using artificial intelligence in the drug discovery process. The company employs a method that combines 3D spatial graph modeling and advanced molecular simulation to identify potential drug candidates. This approach enables them to explore new chemical spaces and discover novel protein targets, which can lead to important new medicines. Unlike many competitors, Genesis Therapeutics operates on a business-to-business model, partnering with other biotech and pharmaceutical companies, such as Eli Lilly, to provide their AI-driven drug discovery services. Their goal is to accelerate the development of new drugs through strategic partnerships and successful collaborations, while also generating revenue from upfront payments and potential future earnings based on the success of the drugs they help discover.
Company Size
51-200
Company Stage
Series B
Total Funding
$272.5M
Headquarters
Burlingame, California
Founded
2019
Simplify's Take
What believers are saying
- Partnership with NVIDIA enhances AI capabilities for drug discovery.
- Strategic collaborations expand therapeutic pipeline and address unmet medical needs.
- Recognition as a 'Fierce 15' company boosts industry credibility.
What critics are saying
- High competition from AI-driven drug discovery companies like Insilico Medicine.
- Over-reliance on partnerships could lead to financial instability.
- Rapid AI advancements may render current models obsolete without continuous innovation.
What makes Genesis Therapeutics unique
- Genesis uses 3D spatial graph modeling for novel drug candidate generation.
- The GEMS platform leverages physics-inspired AI for drug discovery.
- Genesis collaborates with major pharma companies like Eli Lilly and Gilead.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Competitive salary
Equity
Medical, dental, & vision insurance
401(k) program
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 6%2 year growth
↑ 5%Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.
Nvidia’s venture arm, NVentures, has increased its investment in AI drug discovery firm Genesis Therapeutics. Genesis, founded by Evan Feinberg, has raised over $300 million, including a $200 million Series B in 2023. The collaboration aims to enhance Genesis' AI platform, GEMS, for drug discovery. Genesis is also working with Gilead, Eli Lilly, and Genentech on various projects. The company plans to expand its workforce beyond its current 80 employees.
Genesis Therapeutics receives equity investment from NVIDIA.
Genesis Therapeutics has partnered with NVIDIA to enhance its AI platform, GEMS, for drug discovery. This collaboration is supported by additional funding from NVentures, NVIDIA's venture capital arm, following its participation in Genesis' $200 million Series B financing in August 2023. The partnership aims to optimize computational methods like equivariant neural networks to analyze complex 3D molecular structures, targeting diseases with high unmet needs and previously undruggable targets.
Gilead Sciences (GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.